Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05855109 · ClinicalTrials.gov registry record
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,304
- Enrollment target
NCT05855109 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,304 participants.
The verdict
NCT05855109 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,304 participants
- Enrollment target
Study Summary
The overall aim of the study is to develop and validate a Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) clinical prediction model (screening tool) based on risk factors to guide screening for ILD in patients with RA using High Resolution Computed Tomography (HRCT).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,304 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2025-06-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05855109
The ClinicalTrials.gov registry entry for NCT05855109 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05855109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05855109 about?
NCT05855109 is a clinical study titled "Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors". The overall aim of the study is to develop and validate a Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) clinical prediction model (screening tool) based on risk factors to guide screening for ILD in patients with RA using High Resolution Computed Tomography (HRCT).
What is the current status of trial NCT05855109?
This trial is currently completed. The enrollment target is 1,304 participants. The study started on 2023-11-27. Estimated completion is 2025-06-26.
Who is sponsoring clinical trial NCT05855109?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.